Prof. Dr. Gerd Sutter

Weitere Beteiligungen

• 28.03.2023

  • Poster
  • P 293

  Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity

   Adaptive immunity, Vaccines
• 28.03.2023

  • Poster
  • P 312

  In vitro characterization of three MVA based candidate vaccines expressing SARS-CoV-2 envelope, ORF3a and membrane proteins

   Vaccines
• 28.03.2023

  • Poster
  • P 313

  In vitro characterization of two MVA candidate vaccines expressing the fusion and matrix proteins of Nipah virus

   Emerging viruses and zoonosis, Vaccines
• 28.03.2023

  • Poster
  • P 316

  Impact of heterologous MVA-booster vaccination on SARS-CoV-2 specific immune responses in a Golden Syrian Hamster model for Coronavirus disease 2019 (COVID-19)

   Adaptive immunity, Vaccines
• 28.03.2023

  • Poster
  • P 110

  Induction of fetal protection against Zika virus induced by a MVA-prME candidate vaccine

   Emerging viruses and zoonosis, Vaccines
• 28.03.2023

  • Poster
  • P 012

  CD8+ T cell mediated protection against Zika virus induced by recombinant modified Vaccinia virus Ankara expressing ZIKV non-structural protein NS2B

   Adaptive immunity
• 28.03.2023

  • Poster
  • P 317

  Generation and in vitro characterization of two recombinant MVA candidate vaccines expressing Marburg virus glycoprotein and nucleoprotein

   Emerging viruses and zoonosis, Vaccines
• 28.03.2023

  • Poster
  • P 128

  Generation and in vitro characterization of MVA-based vaccines targeting selected influenza A virus hemagglutinin proteins

   Emerging viruses and zoonosis, Vaccines
• 29.03.2023

  11:30 – 11:45 12 Min. 3 Min.

  • Abstract Talk
  • O 047

  Single MVA-MERS-S vaccination activates spike antigen specific T cells in dromedary camels under field conditions

   Adaptive immunity
• 31.03.2023

  10:45 – 11:00 12 Min. 3 Min.

  • Abstract Talk
  • O 115

  MVA-HBVac – a novel vector for treatment of chronic hepatitis B via therapeutic vaccination

   Adaptive immunity, Vaccines